吡非尼酮治疗特发性肺纤维化的研究进展

Research progress of pirfenidone in treatment of idiopathic pulmonary fibrosis

特发性肺纤维化(IPF)是一种有多种危险因素、病因不明、预后不良的肺间质疾病。吡非尼酮是目前获批治疗IPF的两种药物之一。目前基础及临床试验均证实吡非尼酮抗纤维化的有效性,但临床应用中仍存在药物不良反应和个体化差异如体重指数、耐受性等较多问题。本文回顾了近年来吡非尼酮临床应用的相关研究,总结了吡非尼酮应用的安全性、不同剂量吡非尼酮的有效性、可能的影响因素及潜在联合治疗等。

Idiopathic pulmonary fibrosis(IPF)is a specific form of interstitial pneumonia with many risk factors,unknown causes and an unfavorable prognosis.Pirfenidone is currently one of the two approved drugs for the treatment of IPF.At present,the efficacy of pirfenidone against fibrosis has been confirmed by basci trials and clinical trials.However,there are still many problems in the clinical application of pirfenidone including adverse drug reactions and individual differences such as body mass index and tolerance.The related research on the clinical application of pirfenidone in recent years has been reviewed in this article,and the safety of pirfenidone application,the effectiveness of different doses of pirfenidone,possible influencing factors,and potential combination therapy was summarized.